Avalo Therapeutics, Inc.

AVTX Nasdaq SEC CIK 1534120
Follow Avalo Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$18.9M +38.1% vs same quarter last year
EPS, diluted −$0.34 +84.5% vs same quarter last year
Operating cash flow −$11.5M +29.5% vs same quarter last year
Operating income −$23.4M −21.9% vs same quarter last year
Revenue by quarter
$192K
$0
$59K
Q4 24 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$59K−$78.3M
FY24$441K−$35.1M
FY23$1.9M−$31.5M
FY22$18.1M−$41.7M
FY21$5.4M−$84.4M
FY20$6.7M−$63.5M
FY19$6.8M−$16.1M
FY18$7M−$40.1M
FY17$27.8M$11.9M
FY16$1.2M−$16.5M
FY15$0−$10.5M
FY14-−$16.1M
FY13-−$13M
FY12--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−150000%−100000%−50000%0%50000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-−123601.7%−132642.4%
FY24-−15535.6%−7965.8%
FY2333.3%−1421.6%−1639.5%
FY2281%−207.4%−230.8%
FY2172.4%−1521.6%−1563.1%
FY2095.5%−1087.4%−947.9%
FY19-−239.1%−238.1%
FY1853.6%−503.4%−569.9%
FY1797.7%49.9%42.7%
FY16100%−1394.6%−1428.6%
FY15---
FY14---
FY13---
FY12---
Free cash flowOperating cash flow minus capital expenditure
−$75M−$50M−$25M$0$25MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22−$26.8M
FY21−$71M
FY20−$40.6M
FY19−$19.4M
FY18−$3.7M
FY17$12.6M
FY16−$14.6M
FY15−$10.2M
FY14−$15.5M
FY13−$11.5M
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Avalo Therapeutics
  • Healthcare median
−150000%−100000%−50000%0%50000%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearAvalo TherapeuticsHealthcare median
FY25−132642.4%−30.6%
FY24−7965.8%−47%
FY23−1639.5%−58%
FY22−230.8%−80.4%
FY21−1563.1%−71.8%
FY20−947.9%−62.2%
FY19−238.1%−46.2%
FY18−569.9%−49.6%
FY1742.7%−45.9%
FY16−1428.6%−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%